福建广生堂药业股份有限公司关于公司申请向特定对象发行股票的第二轮审核问询函回复的提示性公告

Core Viewpoint - Fujian Guangshentang Pharmaceutical Co., Ltd. is in the process of responding to the second round of inquiry from the Shenzhen Stock Exchange regarding its application for a specific stock issuance, indicating ongoing regulatory scrutiny and the need for compliance with disclosure requirements [1][2]. Group 1 - The company received an inquiry letter from the Shenzhen Stock Exchange on February 6, 2026, regarding its application for a specific stock issuance [1]. - The company, along with relevant intermediaries, has conducted a thorough study and response to the inquiries listed in the letter, which will be disclosed in detail on the company's official information platform [1]. - The stock issuance is subject to approval from the Shenzhen Stock Exchange and the China Securities Regulatory Commission, with uncertainties regarding the approval timeline [2].